Discovery of the First Irreversible HDAC6 Isoform Selective Inhibitor with Potent Anti-Multiple Myeloma Activity
Journal of Medicinal Chemistry · 2023
DOI: 10.1021/acs.jmedchem.3c00977 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Fengling Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of …. Hauptthemen laut MEDLINE: Multiple Myeloma. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Shandong University, National Natural Science Foundation of China, Natural Science Foundation of Shandong Province.
Abstract (Originalsprache)
In our previous research, a series of phenylsulfonylfuroxan-based hydroxamates were developed, among which compound 1 exhibited remarkable in vitro and in vivo antitumor potency due to its histone deacetylase (HDAC) inhibitory and nitric oxide (NO)-donating activities. Herein, the in-depth study of compound 1 revealed that this HDAC inhibitor-NO donor hybrid could enduringly increase the intracellular levels of acetyl histones and acetyl α-tubulin, which could be ascribed to its irreversible inhibition toward class I HDACs and HDAC6. Structural modification of compound 1 led to a novel phenylsulfonylfuroxan-based hydroxamate 4, which exhibited considerable HDAC6 inhibitory activity and selectivity. Furthermore, compound 4 could inhibit intracellular HDAC6 both selectively and irreversibly. To the best of our knowledge, this is the first research reporting the irreversible inhibition of HDAC6. It was also demonstrated that compared with ACY-241 (a reversible HDAC6 inhibitor in clinical trials), the irreversible HDAC6 selective inhibitor 4 exhibited not only superior anti-multiple myeloma activity but also improved therapeutic index.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, P.R. China.
- Department of Pharmacy, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, P.R. China.
- Department of Pharmacy, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, P.R. China.
- Department of Pharmacology and Cancer Biology, Duke University, Durham, North Carolina 27710, United States.
ORCID-Profile: Yingjie Zhang
Förderung
- Shandong University
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province
Zitieren
APA
Liu, F., Liu, C., Chai, Q., Zhao, C., Meng, H., Xue, X., Yao, T. P., & Zhang, Y. (2023). Discovery of the First Irreversible HDAC6 Isoform Selective Inhibitor with Potent Anti-Multiple Myeloma Activity. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c00977
Vancouver
Liu F, Liu C, Chai Q, Zhao C, Meng H, Xue X, et al. Discovery of the First Irreversible HDAC6 Isoform Selective Inhibitor with Potent Anti-Multiple Myeloma Activity. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.3c00977
BibTeX
@article{Liu2023,
author = {Liu, Fengling and Liu, Chunxi and Chai, Qipeng and Zhao, Chunlong and Meng, Hongwei and Xue, Xia and Yao, Tso-Pang and Zhang, Yingjie},
title = {Discovery of the First Irreversible HDAC6 Isoform Selective Inhibitor with Potent Anti-Multiple Myeloma Activity},
journal = {Journal of Medicinal Chemistry},
year = {2023},
doi = {10.1021/acs.jmedchem.3c00977}
}
EUVIMED